dipyridamol
bound
proteas
mpro
identifi
via
virtual
screen
bioassay
valid
thu
suppress
viral
replic
vitro
result
dipyridamol
supplement
associ
significantli
decreas
concentr
ddimer
increas
lymphocyt
platelet
recoveri
circul
markedli
improv
clinic
outcom
comparison
control
patient
abstract
sever
acut
respiratori
syndrom
coronaviru
infect
caus
acut
respiratori
distress
syndrom
hypercoagul
hypertens
multiorgan
dysfunct
effect
antivir
safe
clinic
profil
urgent
need
improv
overal
prognosi
analysi
randomli
collect
cohort
patient
corona
viru
diseas
found
hypercoagul
indic
elev
concentr
ddimer
associ
diseas
sever
virtual
screen
us
food
drug
administr
fda
approv
drug
librari
identifi
anticoagul
agent
dipyridamol
dip
silico
suppress
replic
vitro
proofofconcept
trial
involv
patient
dip
supplement
associ
significantli
decreas
concentr
ddimer
p
increas
lymphocyt
platelet
recoveri
circul
markedli
improv
clinic
outcom
comparison
control
patient
particular
diptreat
sever
ill
patient
show
remark
improv
patient
achiev
clinic
cure
discharg
hospit
remain
patient
clinic
remiss
april
sever
acut
respiratori
syndrom
coronaviru
formerli
known
infect
patient
countri
usa
spain
itali
germani
franc
uk
rapid
spread
declar
global
pandem
date
agent
report
specif
treat
sever
ill
patent
identif
readili
avail
drug
reposit
corona
viru
diseas
therapi
avail
rel
rapid
way
clinic
treatment
togeth
sarscov
merscov
belong
betacoronaviru
genu
envelop
positivestrand
rna
viru
approxim
nucleotid
angiotensin
convert
enzym
receptor
engag
spike
surfac
glycoprotein
sarscov
highli
express
mani
organ
includ
lung
heart
kidney
intestin
notabl
experiment
model
sarscov
infect
spike
protein
engag
decreas
express
activ
reninangiotensin
system
ra
ra
activ
promot
platelet
adhes
aggreg
increas
risk
pulmonari
embol
hypertens
fibrosi
also
acceler
cardiac
kidney
injuri
increas
local
angiotensin
ii
concentr
apart
affect
classic
ra
pathway
defici
intestin
associ
malnutrit
colon
inflamm
infect
sarscov
result
sever
lymphopenia
prolong
coagul
profil
lethal
acut
respiratori
distress
syndrom
ard
wateri
diarrhea
cardiac
diseas
sudden
death
mani
featur
also
report
prolong
coagul
profil
elev
concentr
ddimer
sever
lymphopenia
ard
hypertens
acut
heart
injuri
icuadmit
patient
given
angiotensin
ii
concentr
highli
elev
infect
patient
ra
like
major
pathogen
contributor
diseas
progress
inde
recent
studi
describ
patient
concentr
ddimer
elev
nonsever
sever
case
hospit
admiss
respect
furthermor
zhou
et
al
show
concentr
ddimer
greater
mgl
admiss
associ
significantli
increas
risk
mortal
patient
thu
prophylact
anticoagul
therapi
consid
allevi
multiorgan
damag
patient
viral
entri
host
cell
coronaviru
messeng
rna
first
translat
yield
polyprotein
subsequ
cleav
two
viral
proteinas
proteas
aka
mpro
papainlik
proteas
plp
yield
nonstructur
protein
essenti
viral
replic
inhibitor
suppress
activ
proteas
may
inhibit
viral
replic
offer
avenu
therapi
dipyridamol
dip
antiplatelet
agent
act
phosphodiesteras
pde
inhibitor
increas
intracellular
campcgmp
apart
wellknown
antiplatelet
function
dip
may
provid
potenti
therapeut
benefit
patient
first
publish
studi
includ
clinic
trial
conduct
china
demonstr
dip
broad
spectrum
antivir
activ
particularli
efficaci
positivestrand
rna
virus
second
suppress
inflamm
promot
mucos
heal
third
panpd
inhibitor
dip
may
prevent
acut
injuri
progress
fibrosi
lung
heart
liver
kidney
provid
evid
advoc
dip
adjunct
therapi
virtual
screen
us
food
drug
administr
fda
approv
drug
librari
found
dip
bound
proteas
mpro
fig
support
inform
fig
hydrophob
hydrogen
bond
hbond
interact
main
drive
forc
bind
dip
mpro
free
energi
perturb
calcul
bind
free
energi
pred
kcalmol
predict
ic
pred
valu
nmoll
equat
pred
ln
ic
pred
inhibitori
potenc
dip
mpro
subject
enzymat
assay
use
previous
publish
method
result
dip
exhibit
ic
exp
valu
nmoll
fig
consist
theoret
predict
ic
pred
valu
directli
demonstr
dip
suppress
replic
vitro
measur
viral
titer
use
suscept
cell
line
vero
cell
chloroquin
use
posit
control
remark
concentr
nmoll
dip
suppress
replic
fig
four
time
less
predict
experiment
confirm
ic
suppress
mpro
activ
consist
previou
find
show
dip
possess
addit
antivir
effect
dip
mg
oral
tid
use
patient
prevent
hypercoagul
serum
drug
concentr
report
around
collect
data
suggest
therapeut
dosag
dip
use
treat
hypercoagul
could
potenti
suppress
replic
infect
patient
insert
fig
first
retrospect
analyz
randomli
collect
cohort
patient
reveal
decreas
lymphocyt
count
increas
concentr
ddimer
crp
concentr
significantli
associ
diseas
sever
tabl
evalu
therapeut
potenti
dip
adjunct
therapi
promot
viru
clearanc
baselin
characterist
two
group
shown
tabl
averag
age
patient
year
patient
manifest
cough
short
breath
nausea
vomit
chest
ct
scan
reveal
bilater
pneumonia
diptreat
patient
patient
control
group
addit
rtpcr
test
rna
posit
patient
ddimer
concentr
elev
sever
ill
patient
diptreat
group
control
group
respect
comorbid
includ
diabet
mellitu
cardiovascular
cerebrovascular
diseas
found
patient
dip
control
group
patient
diabet
tabl
treat
insulin
inject
cardiovascular
diseas
treat
nifedipin
insert
tabl
dip
adjunct
therapi
provid
patient
treatment
protocol
compris
mg
oral
tablet
administ
thrice
daili
total
mg
consecut
day
patient
receiv
ribavirin
glucocorticoid
oxygen
therapi
none
receiv
antifung
treatment
mechan
ventil
requir
critic
ill
patient
diptreat
n
sever
critic
ill
patient
control
group
n
treatment
includ
antibiot
vs
intraven
immunoglobulin
vs
dip
adjunct
therapi
associ
markedli
improv
clinic
cure
remiss
rate
nonsever
sever
ill
patient
odd
ratio
p
tabl
particular
sever
ill
patient
diptreat
group
patient
achiev
clinic
cure
discharg
hospit
remain
patient
clinic
remiss
contrast
sever
ill
patient
control
group
patient
discharg
patient
remiss
patient
die
respect
mention
due
urgent
situat
lack
resourc
perform
viral
rna
detect
particip
hospit
unabl
accur
determin
effect
dip
viral
clearanc
howev
accord
qualit
rtpcr
result
rna
provid
local
center
diseas
control
prevent
averag
time
viru
clearanc
shorten
day
sever
case
diptreat
group
comparison
control
group
analysi
laboratori
indic
observ
continu
increas
albeit
statist
signific
count
lymphocyt
platelet
patient
receiv
dip
treatment
comparison
control
patient
fig
given
lymphocytopenia
thrombocytopenia
marker
diseas
sever
patient
immun
recoveri
may
contribut
infect
resolut
diptreat
patient
note
sever
ill
patient
diptreat
control
group
increas
baselin
concentr
ddimer
respect
tabl
calcul
dynam
chang
patient
refer
baselin
valu
found
ddimer
rose
continu
control
group
wherea
decreas
diptreat
group
fig
insert
fig
also
examin
two
critic
ill
patient
receiv
dip
adjunct
therapi
man
suffer
hypoxia
multiorgan
dysfunct
hospit
admiss
unfortun
die
ddimer
concentr
initi
increas
high
mgl
two
day
dip
treatment
gradual
declin
mgl
day
dip
adjunct
therapi
reinforc
high
concentr
ddimer
low
lymphocyt
count
associ
poor
prognosi
suggest
dip
treatment
initi
progress
critic
state
fig
fig
patient
receiv
chest
ct
scan
show
typic
multipl
patchi
groundglass
shadow
lung
treatment
diptreat
patient
lesion
patient
vari
degre
absorpt
treatment
control
group
ct
imag
sever
ill
patient
show
progress
fig
support
inform
tabl
fig
despit
enorm
threat
drug
claim
specif
includ
exist
drug
use
treat
virus
refer
infect
hypothes
spike
protein
engag
may
activ
ra
lung
hypothesi
support
publish
clinic
characterist
biochem
data
sever
critic
ill
patient
show
ard
hypertens
acut
heart
kidney
injuri
posit
ddimer
result
search
avail
anticoagul
focus
dip
broadspectrum
antivir
antiinflammatori
antifibrot
effect
importantli
found
ec
valu
nmoll
suppress
replic
vitro
indic
therapeut
dosag
dip
may
potenti
effect
antivir
respons
infect
patient
find
concord
clinic
find
overal
remark
outcom
sever
ill
patient
receiv
two
week
dip
adjunct
therapi
diptreat
sever
ill
patient
show
remark
improv
dip
treatment
discharg
hospit
show
clinic
remiss
contrast
sever
ill
patient
control
group
discharg
death
occur
recent
public
describ
patient
ddimer
concentr
elev
nonsever
sever
case
hospit
admiss
report
ddimer
concentr
greater
mgl
admiss
associ
significantli
increas
risk
mortal
patient
found
dip
adjunct
treatment
blunt
increas
ddimer
concentr
increas
count
circul
platelet
leucocyt
high
concentr
ddimer
close
correl
pulmonari
embol
vascular
thrombosi
renal
dysfunct
crucial
prognost
factor
import
determin
whether
icupati
recov
sever
infect
thu
prophylact
anticoagul
therapi
dip
consid
patient
reduc
risk
hypercoagul
multiorgan
damag
mention
sever
factor
limit
abil
fulli
investig
therapeut
effect
dip
adjunct
therapi
includ
small
number
enrol
patient
lack
resourc
quantifi
viral
replic
requir
follow
treatment
guidelin
circumst
outbreak
howev
advoc
trial
dip
adjunct
therapi
patient
particularli
earli
sign
elev
concentr
ddimer
dip
use
worldwid
treat
coagulopathi
addit
also
exert
antiinflammatori
antivir
effect
experiment
set
clinic
trial
wide
avail
safeti
afford
dip
argu
investig
therapeut
use
particularli
infect
declar
global
pandem
clinic
trial
regist
inform
written
consent
obtain
patient
condit
patient
monitor
daili
attend
physician
routin
laboratori
test
coagul
variabl
blood
index
carri
treatment
clinic
symptom
laboratori
data
independ
valid
two
independ
investig
assur
data
accuraci
rna
nasopharyng
swab
detect
upon
request
charg
physician
local
center
diseas
control
prevent
wuhan
china
qualit
data
avail
patient
februari
confirm
case
identifi
zhongnan
hospit
wuhan
univers
tabl
anticoagul
therapi
provid
via
oral
dip
tablet
daili
treatment
protocol
compris
possibl
advers
event
patient
receiv
antivir
ribavirin
g
corticoid
methylprednisolon
sodium
succin
mg
qid
oxygen
therapi
nutrit
support
necessari
patient
diabet
treat
insulin
inject
tabl
cardiovascular
diseas
treat
nifedipin
virtual
screen
us
fdaapprov
drug
databas
use
proteas
mpro
drug
target
dip
pubchem
cid
fig
identifi
lead
drug
order
obtain
bind
pattern
calcul
bind
free
energi
dip
mpro
dip
firstli
dock
onto
mpro
use
glidesp
method
default
paramet
optim
bind
pose
fig
assess
absolut
bind
free
energi
calcul
free
energi
perturb
calcul
carri
gromac
thermodynam
cycl
procedur
similar
use
matteo
et
al
calcul
ligand
electrostat
van
der
waal
interact
decoupl
use
linear
alchem
pathway
van
der
waal
electrostat
interact
restraint
ad
keep
rel
posit
receptor
ligand
consist
one
distanc
two
angl
three
dihedr
harmon
potenti
forc
constant
rad
distanc
angl
restraint
determin
valu
last
ns
ns
preliminari
md
simul
fep
calcul
ns
simul
perform
window
sampl
simul
fit
gaussian
algorithm
free
energi
estim
obtain
use
bennet
accept
ratio
bar
method
detail
method
enzymat
assay
mpro
shown
support
inform
statist
analys
graphic
product
perform
use
r
foundat
statist
comput
graphpad
prism
graphpad
softwar
san
diego
ca
usa
categor
variabl
describ
frequenc
percentag
continu
variabl
shown
mean
standard
deviationerror
comparison
two
independ
group
conduct
use
student
test
normal
distribut
data
mannwhitney
test
nonnorm
distribut
data
comparison
laboratori
indic
diptreat
control
group
treatment
cours
conduct
use
gener
mix
linear
model
logist
regress
perform
identifi
factor
associ
clinic
outcom
p
consid
statist
signific
detail
descript
data
comparison
statist
test
specifi
figur
legend
manuscript
scientif
content
author
approv
final
version
articl
author
conflict
interest
declar
tabl
tabl
clinic
variabl
patient
